The association between polymorphisms in the \textit{MDR1} gene and risk of cancer: a systematic review and pooled analysis of 52 case–control studies

Ling-Hui Wang, Yan-Bin Song, Wen-Ling Zheng, Ling Jiang and Wen-Li Ma*

**Abstract**

**Background:** The multidrug resistance (\textit{MDR}) 1 gene encodes a 170-kDa membrane transporter called P-glycoprotein, which plays an important role in protecting cells against lipophilic xenobiotics by the way of an ATP-dependent cellular efflux mechanism. Three polymorphisms of \textit{MDR1}, 3435C > T located in exon 26, 1236C > T in exon 12 and 2677G > T/A in exon 21 were the most extensively studied and were identified functionally important and ethnically diverse mapping to the gene region. Considering the potential influence of altering \textit{MDR1} activity, it is plausible that \textit{MDR1} polymorphisms might play a role in the development of cancer. Although the effects of \textit{MDR1} polymorphisms on susceptibility to human cancer have been investigated in many studies, the results still remain conflicting.

**Methods:** To resolve these conflicts, we performed a quantitative synthesis of the association between these three polymorphisms and cancer risk, including 52 studies (15789 cases and 20274 controls) for 3435C > T polymorphism, 10 studies (2101 cases and 2842 controls) for 1236C > T polymorphism and 18 studies (3585 cases and 4351 controls) for 2677G > T/A polymorphism.

**Results:** The stratified analyses for 3435C > T polymorphism, individuals with T-allele in 3435C > T had significantly higher ALL risks (TT versus CC: OR = 1.286, 95% CI = 1.123-1.474); significantly elevated risks were observed among Caucasian populations (TT versus CC: OR = 1.276, 95% CI = 1.112-1.464). When restricting the analysis to the source of controls, we found that HB (hospital-based) genetic models had higher risks (TT versus CC: OR = 1.307, 95% CI = 1.046-1.632), as well as in PB (population-based) genetic models (TT versus CC: OR = 1.294, 95% CI = 1.079-1.55).

The T/A-allele frequency of 2677G > T/A polymorphism was associated with higher risk of cancer (TT + TA + AA vs. GG: OR = 1.348, 95% CI = 1.031-1.762), significantly elevated risks were observed among Asian populations (TT + TA + AA vs. GG: OR = 1.642, 95% CI = 1.340-2.012), and elevated risks could be associated with PB models (TT + TA + AA vs. GG: OR = 1.641, 95% CI = 1.018-2.646).

**Conclusions:** Our meta-analysis suggested that 3435C > T polymorphism and 2677G > T/A polymorphism were associated with cancer risk when all studies were pooled together, while 1236C > T polymorphism not.

**Keywords:** \textit{MDR1}, Polymorphism, Cancer risk, Meta-analysis
Background

The human multidrug resistance 1 (MDR1 or ABCB1) gene encodes a 170-kDa membrane transport protein called P-glycoprotein. For minimizing the exposure of potential toxic compounds to the cellular homeostasis, P-glycoprotein is expressed primarily in regions that act as epithelial barriers or perform excretory functions, including blood-tissue barrier, the gastrointestinal tract, liver and kidney. Therefore, P-glycoprotein can play the role of sweeper by extruding several exogenous and endogenous substances, using ATP-dependent efflux pump [1-4]. The alteration of the cellular defense mechanism mediated by P-gp has been speculated to be closely associated with the development of various cancers including hepatocarcinoma, colorectal carcinoma, acute lymphoblastic leukemia and gall bladder tumors [5-8]. These suggest that MDR1 may play an important role in the elimination of carcinogens, and the mutation of MDR1 may lead to human malignancies [5]. Several studies try to prove the causal function of P-gp in tumorigenesis by animal experiments. One study by Mochida Y et al. suggested that the absence of the P-gp role suppressed the development of intestinal neoplasia in Apc (Min/+) mice, which lead to human malignancies [5]. Considering these data, we can infer that genetic absence of Pg-p expression may result in more exposure to environmental xenobiotics so that increased opportunity linked to the risk of malignancy was obtained. However, the causal relationship between MDR1 and the tumorigenesis has not been fully elucidated yet.

Recently, at least 50 single-nucleotide polymorphisms have been reported within MDR1 gene locus [12,13]. Among the systematic screens of this gene, Hoffmeyer et al. reported significant role that a synonymous SNP played at position 3435 located in exon 26 in the P-glycoprotein function [14]. Recent studies have found that 3435T was in linkage disequilibrium with two other common SNPs, the synonymous C1236T (exon 12) and nonsynonymous triallelic G2677T/A (exon 21) [15-17].

Considering the potential influence of these SNPs, many molecular epidemiological studies were conducted to investigate the association between these SNPs and cancer risk in humans. However, the results from different studies are to some extent divergent, but nevertheless intriguing, which may be owing to limitations in individual studies. To clarify this issue, we performed a meta-analysis with subgroup analysis from all eligible studies focusing on 3435C > T, 1236C > T and 2677G > T/A, to obtain a more precise estimation of the relationship between polymorphisms and cancer risk.

Material and methods

Identification and eligibility of relevant studies

All case–control studies on the association between MDR1 polymorphisms and cancer risk published up to November 30, 2012 were identified through comprehensive searches using the PubMed and Medline database, ScienceDirect database, Springerlink database, Wiley Online Library, BioMed Central, Nature Series, Science Online, Cell Press Journals, CNKI, WanFang database with the following terms and keywords: “MDR1,” “ABCB1,” “single-nucleotide polymorphism,” and in combination with “leukemia,” “cancer,” “tumor” and “carcinoma.” The search was limited to human studies. In addition, we have especially reviewed the references cited in checked articles and identified some additional articles missed by the searching.

Inclusion criteria

The following criteria were used for the study selection: (1) a case–control study evaluating at least one of these three polymorphisms (3435C > T, 1236C > T and 2677G > T/A) and cancer risk; (2) studies with full-text articles; (3) no overlapping data. and (4) sufficient data for estimating an odds ratio (OR) with 95% confidence interval (95% CI).

Data extraction

Information was carefully extracted from all the eligible publications. The following data were collected from each study: first author's name, publication date, country, ethnicity, cancer type, source of controls (population-based [PB] or hospital-based [HB] controls), genotyping method, total numbers of cases and controls and number of cases and controls for each MDR1 polymorphism. Meanwhile, different case–control groups in one study were considered as independent studies. For each study, we did not define a minimum number of patients for inclusion in our meta-analysis.

Statistical methods

The strength of association between MDR1 polymorphisms and cancer risk was measured by ORs with 95% CIs. The risks (ORs) of cancer associated with the three polymorphisms were estimated for each study. In our study, the C- allele, C-allele and G-allele were considered the reference genotypes, respectively in 3435C > T, 1236C > T and 2677G > T/A. The pooled ORs were performed for co-dominant model (TT vs. CC and TC vs. CC, TT + TA + AA vs. GG and GT + GA vs. GG), dominant model (TC + TT vs. CC, TT + TA + AA + GT + GA vs. GG) and recessive model (TT vs. TC + CC,
TT + TA + AA vs. GT + GA + AA), respectively. Heterogeneity assumption was checked by a $\chi^2$-based Q-test. A p-value of >0.05 for the Q-test indicated a lack of heterogeneity among studies, so that the pooled OR estimate of each study was calculated by the fixed-effects model (the Mantel–Haenszel method). Otherwise, the random-effects model (the DerSimonian and Laird method) was used. Heterogeneity was quantified with the $I^2$ metric, which is independent of the number of studies in the meta-analysis ($I^2 < 25\%$: no heterogeneity; $I^2 = 25–50\%$: moderate heterogeneity; $I^2 = 50–75\%$: large heterogeneity, $I^2 > 75\%$: extreme heterogeneity). Subgroup analyses were performed by cancer type (if one cancer type contained fewer than three individual studies, it was combined into an “other cancers” group), ethnicity and source of controls. Before analysis for each study, we examined whether the genotype distribution of controls was consistent with Hardy–Weinberg equilibrium using the $\chi^2$ test. We performed One-way sensitivity analysis by deleting a single study in the meta-analysis each time to reflect the influence of the individual data set to the pooled OR to assess the stability of the results. An estimate of potential publication bias was carried out by the funnel plot, in which the standard error of log (OR) of each study was plotted against its log (OR). An asymmetric plot suggests a possible publication bias. Funnel plot asymmetry was assessed by the method of Egger’s linear regression test, a linear regression approach to measure funnel plot asymmetry on the natural logarithm scale of the OR. The significance of the intercept was determined by the t-test suggested by Egger ($p < 0.05$ was considered a significant publication bias). All of the statistical tests used in our meta-analysis were performed by SPSS version 13.0 and STATA version 11.0 (Stata, College Station, TX).

**Results**

**Eligible studies and meta-analysis databases**

A total of 48 publications with 52 case–control studies exploring the association between *MDR1* 3435C > T, 1236C > T and 2677G > T/A polymorphisms and cancer risk were found [2,5,18-62]. Hence, as summarized in Table 1, 52 studies (15789 cases and 20274 controls) for 3435C > T polymorphism, 10 studies (2101 cases and 2842 controls) for 1236C > T polymorphism and 18 studies (3585 cases and 4351 controls) for 2677G > T/A polymorphism were selected in the meta-analysis, of which one publications had three independent studies and were considered separately. As summarized in Table 1, there were 25 hospital-based studies and 26 population-based studies. There were 8 acute lymphoblastic leukemia (ALL) studies, 14 colorectal cancer studies, 9 breast cancer studies, 4 gastric cancer studies, 3 renal cell cancer studies, 2 acute myelocytic leukemia (AML) studies, 2 lung cancer study, 2 B-cell chronic lymphocytic leukemia (CLL) studies, one endometrial cancer study, one esophageal squamous cell carcinoma study, one glioma study, one upper aerodigestive tract (UADT) cancers study, one multiple myeloma study, one leukemia study, one plasma cell myeloma study and one study with Hodgkin’s lymphoma (HL). Thirty-three studies were conducted in Europeans, seventeen studies were conducted in Asians. Two of the remained studies were conducted in Americans, and the other was in Mexicans. These studies indicate that the distribution of genotypes in controls was consistent with Hardy–Weinberg equilibrium. And the subjects of controls were matched for age and gender. Most of the cases were confirmed histologically or pathologically.

**Quantitative synthesis**

There was a wide variation in the T-allele and T/A-allele frequency of 3435C > T, 1236C > T and 2677G > T/A polymorphism between the two major ethnicities. For Asians, the T-allele frequency of 3435C > T was 25.52% (95% CI = 23.84–27.21%), which was significantly higher than that in Caucasians (24.28%, 95% CI = 20.54–28.03%, $p < 0.001$). There was no statistical difference for the T-allele frequency of 1236C > T between Asians (24.28%, 95% CI = 11.37–26.56%) and Caucasians (36.11%, 95% CI = 15.74–44.47%, $p = 0.633$). And for Asians (23.47%, 95% CI = 19.78–25.96%) whose T/A-allele frequency of 2677G > T/A polymorphism was not equivalent as Caucasians (22.87%, 95% CI = 11.12–35.82%, $p = 0.633$).

Tables 2 summarizes the main results of the meta-analysis for *MDR1* 3435C > T polymorphisms. Overall, we found that individuals with T-allele in 3435C > T had a higher risk of cancer (co-dominant model TT versus CC: OR = 1.286, 95% CI = 1.123–1.474; CT versus CC: OR = 1.126, 95% CI = 1.020–1.244; dominant model TT + CT versus CC: OR = 1.176, 95% CI = 1.068–1.295; recessive model TT versus CT + CC: OR = 1.191, 95% CI = 1.065–1.333). In the subgroup analysis by cancer type, the results indicated that individuals with T-allele in 3435C > T had significantly higher ALL risks (TT versus CC: OR = 1.890, 95% CI = 1.177–3.037), otherwise no significant association was found between higher CRC risks and T-allele in 3435C > T, neither was between breast cancer and T-allele in 3435C > T. When stratified by ethnicity, significantly elevated risks were observed among Caucasian populations (co-dominant model TT versus CC: OR = 1.276, 95% CI = 1.112–1.464; CT versus CC: OR = 1.172, 95% CI = 1.047–1.313; dominant model TT + CT versus CC: OR = 1.212, 95% CI = 1.083–1.357), whereas significantly elevated risks were not observed among Asian populations (co-dominant model TT versus CC: OR = 1.314, 95% CI = 0.894–1.933). When restricting the analysis to the source of controls, we found that HB genetic models had higher risks (TT versus CC: OR = 1.307,
| References | First author’s name | Year of publication | Country of origin | Cancer type | Ethnicity | SNPs | Source of control groups | Matching criteria | Genotyping methods | Case control | MAF | HWE |
|------------|---------------------|---------------------|-------------------|-------------|-----------|------|--------------------------|-----------------|-------------------|-------------|-----|-----|
| 18         | Rong-rong Liu       | 2008                | Hunan, China      | ALL         | Asian     | C3435T, C1236T, G2677T, G2677T/A | HB              | Age, gender, weight     | PCR-RFLP | 100 | 0.17;0.240;0.04 | 0.60;0.21;0.07 |
| 19         | Zhi-zhuo Du         | 2010                | Suzhou, China     | ALL         | Asian     | C3435T, C1236T, G2677T/A | HB              | Age, gender            | SNP-shot | 176 | 0.30;0.38;0.27 | 0.000;0.28;0.23 |
| 2          | Kevin Y. Urayama    | 2007                | Northern and Central California, USA | ALL | Asian | C3435T, C1236T, G2677T/A | HB              | Age, gender, Hispanic status | PCR-SBEP | 294 | 0.25;0.21;0.18 | 0.30;0.13;0.18 |
| 3          | Hiroyoshi Hattori   | 2007                | Japan             | ALL         | Asian     | C3435T | HB              | Age, gender            | TaqMan | 622 | 0.18 | 0.3  |
| 20         | Jamroziak K         | 2004                | Poland            | ALL         | Caucasian | C3435T | PB              | Age, gender            | PCR-RELP | 113 | 0.24 | 0    |
| 21         | Evelia Leal-Ugarte  | 2008                | Mexico            | ALL         | Hispanic | C3435T | PB              | Gender                 | PCR-RELP | 107 | 0.28 | 0.02 |
| 22         | a’ gnes F. Semsei   | 2008                | Hungary           | ALL         | Caucasian | C3435T, G2677T/A | PB              | Age, gender, risk group | PCR-RELP | 378 | 0.29;0.28 | 0.07;0.13 |
| 23         | Vibeke Andersen     | 2009                | Danish            | colorectal cancer | Caucasian | C3435T, G-3789244-A | PB              | Age, Gender            | TaqMan | 359 | 0.33 | 0.47 |
| 24         | Daniele Campa       | 2012                | Czech Republic    | colorectal cancer | Caucasian | C3435T | HB              | Age, Gender            | TaqMan | 699 | 0.29 | 0.79 |
| 25         | Uros’ Potocnik      | 2008                | Slovenia          | MSI-H colorectal cancer | Caucasian | C3435T, C1236T, G2677T | HB              | Age, Gender            | TaqMan | 38  | 0.30;0.18;0.19 | 0.66;0.33;0.24 |
| 26         | Nizar M Mhaidat     | 2011                | Jordan            | HL          | Asian     | C3435T | HB              | Age                  | PCR-RFLP | 130 | 0.35 | 0.11 |
| 27         | Sun-Young Bae       | 2006                | Korea             | colorectal cancer | Asian | C3435T | HB              | Age, Gender            | PCR-RFLP | 111 | 0.16 | 0.01 |
| 28         | Azam Khedri         | 2011                | Iran              | colorectal cancer | Caucasian | C3435T | HB              | Age, Gender            | PCR-RFLP | 118 | 0.35 | 0.56 |
| 29         | Mateusz Kurzawski   | 2005                | Poland            | colorectal cancer | Caucasian | C3435T | HB              | Age, Gender            | PCR-RFLP | 184 | 0.29 | 0.27 |
| 30         | Chiko Komoto        | 2006                | Japan             | colorectal cancer | Asian | C3435T, C1236T, G2677T | HB              | Age, Gender            | TaqMan | 48  | 0.16;0.375;0.36 | 0.62;0.36;0.37 |
| No. | Study | Year | Country | Tissue Type | Ethnicity | Mutation Sites | Method | Age Range | Gender | TaqMan/PCR-RFLP | OR | 95% CI | P Value |
|-----|--------|------|---------|-------------|-----------|----------------|--------|------------|--------|----------------|----|--------|---------|
| 30  | Chiko Komoto | 2006 | Japan | esophageal squamous cell carcinoma | Asian | C3435T, C1236T, G2677T | HB Age, Gender, TaqMan | 47 | 154 | 0.17;0.39;0.34 | 0.66;0.34;0.64 |
| 31  | Bo-In Lee | 2006 | Korea | colorectal cancer | Asian | C3435T | HB Age, Gender, PCR-RFLP | 64 | 64 | 0.13 | 0.15 |
| 32  | Elena Osswald | 2006 | Russia | colorectal cancer | Caucasian | C3435T, C1236T, G2677T/A | HB Age, Gender, Smoking intensity | 285 | 275 | 0.26;0.20 | 0.35;0.42 |
| 33  | Mariusz Panczyk | 2009 | Poland | colorectal cancer | Caucasian | C3435T, C1236T, G2677T | HB Age, Gender, PCR-RFLP | 95 | 95 | 0.20;0.17;0.18 | 0.99;0.72;0.60 |
| 34  | Darinka Todorova Petrova | 2008 | Bulgaria | colorectal cancer | Caucasian | C3435T, C1236T, G2677T | HB Age, Gender, RT-PCR | 146 | 160 | 0.25;0.21 | 0.73;0.32 |
| 35  | J Sainz | 2011 | South Germany | colorectal cancer | Caucasian | C3435T | PB Age, Gender, PCR | 1765 | 1784 | 0.27 | 0.6 |
| 36  | Cizmarikova | 2010 | Eastern Slovakia | breast cancer | Caucasian | C3435T | PB Age, Gender, PCR-RFLP | 221 | 113 | 0.27 | 0.6 |
| 37  | M. Taferi | 2010 | Iran | breast cancer | Caucasian | C3435T | HB Age, Gender, PCR-RFLP | 54 | 50 | 0.26 | 0.61 |
| 38  | Tatari F | 2009 | North east of Iran | breast cancer | Caucasian | C3435T | HB Gender, PCR | 106 | 77 | 0.29 | 0.59 |
| 39  | Joseph George | 2009 | India | breast cancer | Asian | C3435T | HB Gender, PCR | 86 | 68 | 0.15 | 0.7 |
| 40  | Henriquez-Hernandez | 2009 | Spain | breast cancer | Caucasian | C3435T | PB Gender, PCR-RFLP | 135 | 301 | 0.19 | 0.66 |
| 41  | Nordgard | 2007 | Norway | breast cancer | Caucasian | C3435T, C1236T, G2677T/A | N.A. Age, Gender, PCR-RFLP | 109 | 93 | 0.13;0.26|0.26 | 0.27;0.16;0.03 |
| 42  | Sebahat Turugt | 2007 | Turkey | breast cancer | Caucasian | C3435T | PB Gender, PCR-RFLP | 57 | 50 | 0.24 | 0.62 |
| 43  | Wu H | 2012 | China | breast cancer | Asian | C3435T, C1236T, G2677T/A | PB Age, Gender, PCR-RFLP | 1173 | 1244 | 0.17;0.41;0.17 | 0.01;0.04;0.94 |
| 44  | Z Sabahi | 2010 | Iran | Gastric cancer | Caucasian | C3435T | PB Age, Gender, PCR | 48 | 131 | 0.3 | 0.58 |
| 45  | Mitsushige Sugimoto | 2008 | Japan | Gastric cancer | Asian | C3435T | HB Age, Gender, PCR-RFLP | 150 | 168 | 0.17 | 0.68 |
| 46  | Tomomitsu Tahara | 2006 | Japan | Gastric cancer | Asian | C3435T | HB Age, Gender, PCR-RFLP | 157 | 104 | 0.21 | 0.64 |
| 47  | P.M. MROZIKIEWICZ | 2007 | Poland | endometrial cancer | Caucasian | C3435T | PB Age, Gender, PCR | 198 | 488 | 0.26 | 0.61 |
| 48  | Federica Gemignani | 2007 | six Central and Eastern European countries | lung cancer | Caucasian | C3435T, G2677T/A | HB Age, Gender, TaqMan | 299 | 317 | 0.24;0.21 | 0.62;0.01 |
| 49  | S Haenisch | 2007 | Germany | renal cell cancer | Caucasian | C3435T, G2677T/A | PB Age, Gender, PCR-RFLP | 82 | 164 | 0.31;0.22 | 0.58;0.14 |
| Study Number | Author(s) | Year | Country | Ethnicity | Tumor Type | Study Design | Genotype | Age | Gender | PCR-RFLP | Minor Allele Frequency | P Value |
|-------------|------------|------|---------|-----------|------------|--------------|----------|-----|--------|----------|-------------------|---------|
| 50          | Krzysztof Jamroziak | 2006 | Poland | Caucasian | AML | PB | C3435T | 180 | Age, Gender | 180 | 0.23 | 0.64 |
| 51          | Katie L. Miller | 2005 | USA    | Caucasian | Glioma | PB | C3435T | 382 | Age, Gender | 464 | 0.25 | 0.61 |
| 52          | Krzysztof Jamroziak | 2006 | Poland | Caucasian | B-cell CLL | PB | C3435T | 110 | Age, Gender | 201 | 0.2 | 0.65 |
| 53          | Michael Siegsmund | 2002 | Germany | Caucasian | clear cell renal cell carcinoma (CCRCC) | PB | C3435T | 179 | Age, Gender | 150 | 0.29 | 0.59 |
| 54          | Guillermo Gervasini | 2006 | Spain  | Caucasian | lung cancer | PB | C3435T, G2677T/A | 96 | Age, Gender | 86 | 0.26, 0.31 | 0.61, 0.6 |
| 55          | Soya Sisy Sam | 2007 | India  | Asian | upper aerodigestive tract (UADT) cancers | HB | C3435T | 219 | Age, Gender | 210 | 0.35 | 0.55 |
| 56          | Krzysztof Jamroziak | 2008 | Poland | Caucasian | multiple myeloma | PB | C3435T, C3435T, G2677T/A | 111 | Age, Gender | 96 | 0.31, 0.15, 0.01 | 0.65, 0.01, 0.55 |
| 57          | V Rocha | 2008 | France | Caucasian | leukemia | PB | C3435T | 107 | Age, Gender | 107 | 0.2 | 0.65 |
| 58          | STEPHEN DRAIN | 2009 | UK     | Caucasian | plasma cell myeloma | PB | C3435T | 92 | Age, Gender | 92 | 0.28 | 0.6 |
| 59          | G. Penna | 2010 | Italy  | Caucasian | B-cell CLL | PB | C3435T, G2677T | 125 | Age, Gender | 125 | 0.25, 0.30 | 0.62, 0.00 |
| 60          | The MARIE-GENICA Consortium | 2010 | Germany | Caucasian | breast cancer | PB | C3435T | 3148 | Age, Gender | 5486 | 0.22 | 0.64 |
| 61          | HYUN CHANG | 2009 | Korea  | Caucasian | Gastric cancer | PB | C3435T, G2677T/A | 43 | Age, Gender | 118 | 0.34, 0.23 | 0.56, 0.21 |
| 62          | D Nageswara Rao | 2010 | India  | Asian | AML | PB | C3435T | 143 | Age, Gender | 249 | 0.28 | 0.6 |
| 63          | D Nageswara Rao | 2010 | India  | Asian | ALL | PB | C3435T | 147 | Age, Gender | 249 | 0.37 | 0.54 |

Abbreviations: HB: hospital-based; PB: population-based; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; MAF: minor allele frequency; APEX: arrayed primer extensions.
| Genetic model | Sample size (case/control) | OR (95% CI) | p    | I² (%) | OR (95% CI) | p    | I² (%) | OR (95% CI) | p    | I² (%) | OR (95% CI) | p    | I² (%) |
|---------------|---------------------------|-------------|------|--------|-------------|------|--------|-------------|------|--------|-------------|------|--------|
| C343ST        | 52(15789/20274)           | 1.286(1.123-1.474) | 0.000 | 71.30% | 1.126(1.020-1.244) | 0.000 | 58.20% | 1.176(1.068-1.295) | 0.000 | 61.60% | 1.191(1.065-1.333) | 0.000 | 73.00% |
| Cancer types  |                           |             |      |        |             |      |        |             |      |        |             |      |        |
| Acute lymphoblastic leukemia (ALL) | 8(1381/1459)    | 1.890(1.177-3.037) | 0.000 | 77.60% | 0.981(0.683-1.410) | 0.001 | 70.10% | 1.240(1.046-1.470) | 0.153 | 34.50% | 1.829(1.095-3.054) | 0.000 | 87.30% |
| Colorectal cancer | 14(6362/7274)   | 1.047(0.875-1.254) | 0.006 | 55.90% | 1.053(0.906-1.224) | 0.013 | 51.80% | 1.054(0.907-1.225) | 0.005 | 56.60% | 1.014(0.939-1.094) | 0.037 | 44.50% |
| Breast cancer  | 9(5073/7498)       | 1.187(0.869-1.621) | 0.001 | 69.30% | 0.992(0.912-1.079) | 0.190 | 28.70% | 1.098(0.906-1.331) | 0.024 | 54.80% | 1.134(0.905-1.420) | 0.017 | 57.10% |
| Ethnicity      |                           |             |      |        |             |      |        |             |      |        |             |      |        |
| Caucasian     | 33(12146/15989)      | 1.276(1.112-1.464) | 0.000 | 60.40% | 1.172(1.047-1.313) | 0.000 | 64.9%  | 1.212(1.083-1.357) | 0.000 | 60.2%  | 1.062(1.005-1.122) | 0.001 | 47.7%  |
| Asian         | 17(2966/3418)       | 1.134(0.894-1.493) | 0.000 | 80.4%  | 1.072(0.837-1.374) | 0.000 | 67.4%  | 1.153(0.915-1.453) | 0.000 | 67.9%  | 1.236(0.867-1.763) | 0.000 | 84.4%  |
| Source of control |                   |             |      |        |             |      |        |             |      |        |             |      |        |
| HB            | 25(5553/6173)       | 1.307(1.046-1.632) | 0.000 | 69.10% | 1.090(0.913-1.302) | 0.000 | 64.60% | 1.170(1.009-1.357) | 0.001 | 54.90% | 1.221(0.995-1.498) | 0.000 | 76.80% |
| PB            | 26(10143/13992)     | 1.294(1.079-1.532) | 0.000 | 73.90% | 1.150(1.019-1.299) | 0.003 | 53.20% | 1.475(1.267-1.726) | 0.000 | 77.60% | 1.183(1.033-1.355) | 0.000 | 69.60% |
| C1236T        | 10(2101/2842)       | 1.325(0.824-2.133) | 0.000 | 77.10% | 1.133(0.817-1.573) | 0.005 | 62.20% | 1.173(0.825-1.668) | 0.000 | 70.60% | 1.191(0.840-1.690) | 0.000 | 77.80% |
| G2677T/A      | 18(3585/4351)       | 1.348(1.031-1.762) | 0.000 | 68.70% | 1.096(0.986-1.218) | 0.136 | 27.50% | 1.161(1.051-1.281) | 0.019 | 45.50% | 1.278(1.022-1.597) | 0.000 | 68.00% |
| Ethnicity      |                           |             |      |        |             |      |        |             |      |        |             |      |        |
| Caucasian     | 11(1728/1950)       | 1.363(0.921-2.016) | 0.000 | 73.60% | 1.081(0.852-1.373) | 0.029 | 50.10% | 1.149(0.890-1.467) | 0.007 | 58.80% | 1.271(0.906-1.782) | 0.000 | 74.60% |
| Asian         | 6(1583/2040)        | 1.642(1.340-2.012) | 0.142 | 39.50% | 1.153(0.989-1.344) | 0.804 | 0.00%  | 1.273(1.101-1.471) | 0.643 | 0.00%  | 1.481(1.244-1.763) | 0.192 | 32.50% |
| Source of control |                   |             |      |        |             |      |        |             |      |        |             |      |        |
| HB            | 10(1489/2220)       | 1.036(0.847-1.267) | 0.045 | 47.80% | 1.025(0.874-1.202) | 0.072 | 43.00% | 1.032(0.888-1.198) | 0.077 | 42.10% | 1.028(0.887-1.219) | 0.137 | 33.90% |
| PB            | 7(2005/2022)        | 1.641(1.018-2.646) | 0.000 | 77.20% | 1.164(1.008-1.345) | 0.418 | 0.70%  | 1.284(1.122-1.470) | 0.099 | 43.80% | 1.537(0.998-2.366) | 0.000 | 80.10% |

HB: hospital-based; PB: population-based.
95% CI = 1.046–1.632; dominant model: OR = 1.170, 95% CI = 1.098–1.357), and association was detected in PB genetic models also (TT versus CC: OR = 1.294, 95% CI = 1.079–1.552; CT versus CC: OR = 1.150, 95% CI = 1.019–1.299; dominant model TT + CT versus CC: OR = 1.459, 95% CI = 1.246–1.709; recessive model TT versus CT + CC: OR = 1.183, 95% CI = 1.033–1.355) (Figure 1).

We also found that T/A-allele frequency of 2677G > T/A polymorphism was associated with higher risk of bearing cancer (2677G > T/A: TT + TA + AA vs. GG: OR = 1.348, 95% CI = 1.031–1.762; dominant model: OR = 1.161, 95% CI = 1.051–1.281; recessive model: OR = 1.278, 95% CI = 1.022–1.597). In the subgroup analysis by ethnicity, significantly elevated risks were observed among Asian populations (co-dominant model TT + TA + AA vs. GG: OR = 1.642, 95% CI = 1.340–2.012; dominant model: OR = 1.273, 95% CI = 1.101–1.471; recessive model: OR = 1.481, 95% CI = 1.244–1.763), however no significantly elevated risks were observed among Caucasian populations.

When stratified by the source of controls, we couldn’t find association between HB genetic models and higher cancer risks, but elevated risks could be associated with PB models (TT + TA + AA vs. GG: OR = 1.641, 95% CI = 1.018–2.646; GA + GT vs. GG: OR = 1.164, 95% CI = 1.008–1.345; dominant model: OR = 1.284, 95% CI = 1.122–1.470).

The combined result based on all studies showed that there was no statistically significant link between cancer risk and 1236C > T (1236C > T: TT vs. CC: OR = 1.325, 95% CI = 0.824–2.133; CT vs. CC: OR = 1.133, 95% CI = 0.817–1.573; dominant model: OR = 1.173, 95% CI = 0.825–1.688; recessive model: OR = 1.191, 95% CI = 0.840–1.690) (Table 2).

### Heterogeneity and sensitivity analyses

For 3435C > T polymorphism, there was substantial heterogeneity among studies for homozygote comparison (TT vs. CC: p heterogeneity = 0.000), and recessive model comparison (TT vs. CT + CC: p heterogeneity < 0.001).

---

**Figure 1** Forest plot of cancer risk associated with the MDR1 3435C > T polymorphism (TT vs. CC, random effects). The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the study-specific weight (inverse of the variance). The diamonds represent the pooled OR and 95% CI.
Then, we assessed the source of heterogeneity for homozygote comparison (TT vs. CC) by ethnicity, cancer type and source of controls. We found that cancer type ($\chi^2 = 18.51$, df = 2 and $p < 0.001$), ethnicity ($\chi^2 = 9.58$, df = 1 and $p = 0.002$) and the source of controls ($\chi^2 = 4.42$, df = 1 and $p = 0.036$) all contributed to substantial heterogeneity. Although the sample size for cases and controls in 52 studies ranged from 38 to 5,486, the corresponding pooled ORs were not qualitatively altered with or without the study of small sample. Similarly, no other single study influenced the pooled OR materially as indicated by sensitivity analysis.

And for 2677G > T/A polymorphism, there was also heterogeneity for homozygote comparison (TT + TA + AA vs. GG: $p$ heterogeneity = 0.000), recessive model comparison ($p$ heterogeneity < 0.001). The heterogeneity we decided to analyze was homozygote comparison (TT + TA + AA vs. GG). Due to cancer type ($\chi^2 = 20.14$, df = 7 and $p = 0.005$) and the source of controls ($\chi^2 = 14.53$, df = 1 and $p < 0.001$), but not the ethnicity ($\chi^2 = 1.28$, df = 1 and $p = 0.258$).

**Publication bias**

We performed Begg’s funnel plot and Egger’s test to assess the publication bias of literatures. As shown in Figure 2, the shape of the funnel plots did not reveal any evidence of obvious asymmetry. The results of Egger’s test still did not suggest any evidence of publication bias for 3435C > T polymorphism ($p = 0.085$ for TT vs. CC, $p = 0.273$ for CT vs. CC, $p = 0.102$ for dominant model, respectively and $p = 0.176$ for recessive model). There are neither Publication bias for 1236C > T polymorphism ($p = 0.247$ for TT vs. CC, $p = 0.208$ for CT vs. CC, $p = 0.215$ for dominant model, respectively and $p = 0.332$ for recessive model), nor for 2677G > T/A polymorphism ($p = 0.716$ for TT + TA + AA vs. GG and $p = 0.656$ for recessive model, $p = 0.841$ for GT + GA vs. GG, $p = 0.971$ for dominant model, respectively).

**Discussion**

ATP-binding cassette (ABC) is one of the largest families of active importers and exporters that are located mainly in tissues acting as a barrier or having an excretory function. Most of the ABC transporters play a role in cell defense against environmental attacks generated by xenobiotics and intracellular metabolic waste. The multidrug resistance 1 (MDR1/ABCB1) gene codes for P-glycoprotein, a membrane-bound transporter. Various cytokines, such as interleukin-1beta, benzo [a]pyrene and chemokines involved in inflammation seem to be the substrates of P-glycoprotein, which leading P-glycoprotein to be a potential cause of inflammation-induced carcinogenesis. MDR1 also seems to play a role in preventing early apoptosis in tumor cells.

Significant MDR1 gene heterogeneity, namely multiple mutations in the ABCB1/MDR1 gene has been demonstrated in previous studies. Analysis of all 28 exons of the ABCB1/MDR1 gene demonstrated at least 48 single-nucleotide polymorphisms (SNPs) to date, including promoter and the intron–exon region. The most frequent SNP MDR1 2677G > T/A in exon 21 (RefSNP ID: rs2032582), leads to amino acid exchange from Ala to Ser or Thr. The silent mutation in exon 26 MDR1 3435C > T (RefSNP ID: rs1045642) is associated with altered protein function. The third common polymorphism of ABCB1/MDR1 gene is a silent mutation in exon.

**Figure 2** Begg’s funnel plots for publication bias test (3435C > T TT vs. CC). Each point represents a separate study for the indicated association. Log (OR), natural logarithm of OR. Horizontal line, means effect size.
Our results showed that \textit{MDR1} 3435C > T polymorphism is associated with cancer risk when all studies were pooled together (TT versus CC: OR = 1.286, 95% CI = 1.020–1.244; dominant model TT + CT versus CC: OR = 1.176, 95% CI = 1.068–1.295; recessive model TT versus CT + CC: OR = 1.191, 95% CI = 1.065–1.333). In the stratified analysis by cancer type, the results indicated that individuals with T-allele in 3435C > T had significantly higher ALL risks (TT versus CC: OR = 1.890, 95% CI = 1.177–3.037; TT + CT versus CC: OR = 1.240, 95% CI = 1.046–1.470; recessive model TT versus CT + CC: OR = 1.829, 95% CI = 1.095–3.054), otherwise no significant association was found between higher CRC risks and T-allele in 3435C > T, neither was between breast cancer and T-allele in 3435C > T. When stratified by ethnicity, significantly elevated risks were observed among Caucasian populations (co-dominant model TT versus CC: OR = 1.276, 95% CI = 1.112–1.464; CT versus CC: OR = 1.172, 95% CI = 1.047–1.313; dominant model TT + CT versus CC: OR = 1.212, 95% CI = 1.083–1.357), whereas significantly elevated risks were not observed among Asian populations (co-dominant model TT versus CC: OR = 1.314, 95% CI = 0.894–1.933). When restricting the analysis to the source of controls, we found that HB genetic models had higher risks (TT versus CC: OR = 1.307, 95% CI = 1.046–1.632; dominant model: OR = 1.170, 95% CI = 1.009–1.357), and association was detected in PB genetic models also (TT versus CC: OR = 1.294, 95% CI = 1.079–1.552; CT versus CC: OR = 1.150, 95% CI = 1.019–1.299; dominant model TT + CT versus CC: OR = 1.459, 95% CI = 1.246–1.709; recessive model TT versus CT + CC: OR = 1.183, 95% CI = 1.033–1.355).

Inconsistent results might be attributed to the different roles \textit{MDR1} played in different cell types or tissues. We’ve found the association between \textit{MDR1} 3435C > T polymorphism and ALL risk in subgroup analyses, as well as subgroup based on HB and PB genetic models. And in the stratified analysis by ethnicity, individuals carrying the T-allele in 3435C > T were significantly associated with elevated cancer risk in Asian as well as Caucasian populations compared with C-allele carriers.

We also found that T/A-allele frequency of 2677G > T/A polymorphism was associated with higher risk of cancer (2677G > T/A: TT + TA + AA vs. GG: OR = 1.348, 95% CI = 1.031–1.762). In the subgroup analysis by ethnicity, significantly elevated risks were observed among Asian populations (co-dominant model TT + TA + AA vs. GG: OR = 1.642, 95% CI = 1.340–2.012), however no significantly elevated risks were observed among Caucasian populations. When stratified by the source of controls, we couldn’t find association between HB genetic models and higher cancer risks, but elevated risks could be associated with PB models (TT + TA + AA vs. GG: OR = 1.641, 95% CI = 1.018–2.646; GA + GT vs. GG: OR = 1.164, 95% CI = 1.008–1.345; dominant model: OR = 1.284, 95% CI = 1.122–1.470).

The combined result based on all studies showed that there was no statistically significant link between cancer risk and 1236C > T (1236C > T: TT vs. CC: OR = 1.325, 95% CI = 0.824–2.133; CT vs. CC: OR = 1.133, 95% CI = 0.817–1.573; dominant model: OR = 1.173, 95% CI = 0.825–1.688; recessive model: OR = 1.191, 95% CI = 0.840–1.690).

It should be considered that the apparent inconsistency of these results may be caused by differences in disease prevalence, lifestyle, as well as possible limitations due to the relatively small sample size. The current knowledge of carcinogenesis indicates it is a process developed step by step, as well as influenced by multiple factors that involve various genetic alterations and several signaling pathways. Thus, it is unlikely that risk factors of cancer work in isolation from each other. Besides, even the same polymorphisms may act distinct roles in each cancer type, for different genetic backgrounds may contribute to the cancer discrepancy. And more importantly, the appearance determined by polymorphisms may largely depend on synthetically interaction with each polymorphism or a particular environmental exposure. Thus, it is possible that the effects of DNA repair function on cancer risk may be modified by multiple genetic polymorphisms. Thus we should also consider the chance findings as another plausible reason for the inconsistency of the results.

Although we have put considerable resources and efforts into discovering the association between \textit{MDR1} polymorphism and cancer risk as possible as we can, there still exists some limitations. First, when stratified by the source of controls, our results indicated that studies using hospital-based controls rather than population-based controls had a significantly increased risk. The reason may be that the hospital-based studies have some biases because such controls may contain certain other diverse diseases which can cause different risks of developing into cancer of various organs and may not be so representative as the general population. Therefore, using proper and more representative cancer-free control subjects are crucial for reducing biases in such case–control studies. Second, our results were based on single-factor estimates without adjustment for other risk factors such as age, smoking and drinking status, environmental factors and other variables, which might have
caused serious confounding bias. Third, some inevitable publication bias might exist. Finally, the number of the published studies was not sufficiently large for a comprehensive analysis, particularly for the 1236C > T polymorphism. Hence we had to give up subgroup analysis for the polymorphism. For these limitations, our results should be interpreted with caution.

Our meta-analysis also has several strengths. First, statistically, a systematic review of the association of MDR1 polymorphism between cancer risks is more powerful than any single study. Second, the quality of eligible studies included in current meta-analysis was satisfactory and met our inclusion criterion. Third, we did not detect sufficient publication bias indicating that the whole results might not be unbiased.

In conclusion, our meta-analysis suggests that the MDR1 3435C > T and 2677G > T/A polymorphism may contribute to genetic susceptibility of cancers. And the results support that the minor T-allele of the MDR1 3435C > T polymorphism is associated with a higher risk of acute lymphocytic leukemia, and significantly elevated risks were observed among Asian and Caucasian populations as well as HB and PB subgroups. And in the 2677G > T/A polymorphism, those who carry the T-allele and A-allele were associated with higher cancer risks among Asians and PB subgroup. However, it is necessary to conduct large sample studies using standardized unbiased genotyping methods, homogeneous cancer patients and well-matched controls. Moreover, further studies estimating the effect of gene–gene and gene–environment interactions may eventually lead to our better, comprehensive understanding of the association between the MDR1 polymorphism and cancer risk.

Abbreviations
95%CI: 95% confidence interval; OR: Odds ratio; ALL: Acute lymphoblastic leukemia; HL: Hodgkin lymphoma; HB: Hospital-based; PB: Population-based; PCR-ARLP: Polymerase chain reaction-restriction fragment length polymorphism; MAF: Minor allele frequency; APEX: Arrayed primer extensions.

Competing interests
The author declares that there are no competing interests and that this work has not been published or submitted concurrently for publication elsewhere.

Authors’ contributions
LHW contributed solely to the writing and submission of this work. All authors read and approved the final manuscript.

Acknowledgements
The author would like to acknowledge the Guangdong Supporting Grant for Outstanding Talents (2001–12) that led to the writing of this work.

Received: 11 December 2012 Accepted: 23 April 2013 Published: 20 May 2013

References
1. Laura M, Hodges SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB: Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 2011, 21(1):152–161.
2. Urayama KY, Wieneke JK, Buehler PA, Chokkalingam AP, Metayer C, Wiemels JL: MDR1 Gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev 2007, 16(12):1172–1177.
3. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999, 39:361–398.
4. Schinkel AH: The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997, 8:161–170.
5. Hattori H, Suminoo A, Morimasa W, Yuhi K, Kimitoshi K, Okamura J, Toshiro H, Akinobu M: Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukemia. Leuk Res 2007, 31:1653–1660.
6. Wang BL, Zhai HY, Chen BY, Zhai SP, Yang HY, Chen XP, et al: Clinical relationship between MDR1 gene and gallbladder cancer. Hepatobiliary Pancreat Dis Int 2004, 3:296–299.
7. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, et al: Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991, 51:2720–2726.
8. Thorgeirsson SS, Huber BE, Sorrell S, Fojo A, Pastan I, Gottesman MM: Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 1987, 236:1120–1122.
9. Mochida Y, Taguchi K, Taniguchi S, Tsuneyoshi M, Kuwano H, Tsuzuki T, Michikoh K, Morimasa W: The role of P-glycoprotein in intestinal tumorigenesis: disruption of mdr1a suppresses polypl formation in Apo (Min+)/+mice. Carcinogenesis 2003, 24:219–1224.
10. Yamada T, Mori Y, Hayashi R, Takada M, Ino Y, Naishiro Y, Tadashi K, Setsuo H: Suppression of intestinal polyplsy in Mdr-1-deficient ApoMin/+ mice. Cancer Res 2003, 63:895–901.
11. Schinkel AH, Smit JM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus Maandag EC, te Riele HP, Berens AIM, Borst P: Disruption of the mouse mdr1a-P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell 1994, 77:491–502.
12. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffer E, Eichelbaum M, Brinkmann U, Roots I: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001, 69:169–174.
13. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Styke D, Ferrin TE, DeYoung J, Taylor T, Carlson EL, Herskovitz I, Giacomini KM, Clark AG, Pharmacogenetics of Membrane Transporters Investigators: Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003, 13:481–494.
14. Hoffmeyer S, Burk O, van Richter O, Arnold HP, Brockmöller J, Johne A, Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999, 39:361–398.
15. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 2009, 19(3):206–216.
16. Sai K, Kaniva N, Itoha M, Saito Y, Hasegawa R, Komamura K, Ueno K, Kamakura T, Ikatake M, Shirai X, Minami H, Hoshia A, Yoshida T, Sajo N, Itamura Y, Kamata N, Ozawa S, Sawada J, Haplotypysis analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenomics 2003, 13:741–757.
17. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002, 12:457–459.
18. Rongrong L: The role of multidrug resistance gene 1 polymorphism to prognosis of adult acute lymphoblastic leukemia patients. Central South University 2008, 51–48.
19. Zhi-zhuo D: The singnificance of the expression of the CYP3A5 and MDR1 genetic polymorphism in childhood acute lymphoblastic leukemia. Journal Of Clinical Pediatrics 2011, 29:3283–289.
20. Jarroziak KM, Linyarski W, Balercz Z, Slupianek A, Mirecka A, Marisak A, Mokrzycka T, Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004, 72(3):314–321.

21. Pedria L, Melka G-A, Macías-Gómez NM, Valeria P-L, Jorge D-G, María de la Luz A-M, Miriam P-P, Patricia B-N, Dinorah R-D, Moreno-Ortiz J-M, Jorge P-S, Juan Pablo M-E: MDR1 C3435T Polymorphism in Mexican children with acute lymphoblastic leukemia and in healthy individuals. Human Biol 2008, 80(4):449–455.

22. Agnes F, Sensio Daniel J, Edelby I, Ungvari E, Karmy Be la C, Hajnalka A, Attila T, Edit C, Andreas F, Kovacs GT, Csaba S: Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukemia. Leukemia Res 2008, 32:1214–1220.

23. Vibeke A, Lene A, Dorte A, Østergaard M, Sæbø M, Hamfjord J, Kure E, Vogel WJ, Mahasneh IO, Aldaher AN: The significance of C3435T point mutation of MDR1 gene in colon cancer patients. Carcinogenesis 2006, 27(12):2173–2178.

24. Campa D, Sainz J, Pardini B, Vodickova L, Naccarati A, Rudolph A, Novotny J, Canzian F, Glava D, Dean M: Common germline MDR1 ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability. Cancerogenesis 2008, 18(2):28–34.

25. Mhaidat NM, Alshogran OY, Khbouri OF, Abouzib KH, Matlaha II, Haddadin WJ, Mahanen IQ, Aldaher AN: Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin’s Lymphoma. J Exp Clin Cancer Res 2011, 30(8):1–8.

26. Bae S-Y, Sun-Keun C, Kyung-Rae K, Chang-Shin P, Sung-Keun L, Hyung-Keun R, Dong-Woong S, Jae-Eun P, Ze-Hong W, Ju-Hee K: Effects of genetic polymorphisms of MDR1, MFO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. Cancer Sci 2006, 97(7):749–754.

27. Khedri A, Nejat-Shokouhi A, Salek R, Esmaeili H, Mokhtarifar A, Heravi RE, Northrup RM, Dvorak M, Schmaler A, Crowell D, Husein A: The influence of polymorphisms of ABCB1 gene on colorectal cancer in the Iranian population. Cancer Sci 2009, 100:177–183.

28. Kurzawski M, Drozdzik M, Suchy J, Kurzawski G, Bialy MP, Balcerc Zak E, Mistygacz M, Trelin Ska J, Mirowski M, Bodalski J, Robak T: The C3435T polymorphism of MDR1 gene with childhood acute lymphoblastic leukemia. Arch Immunol Ther Exp 2006, 54(6):217–220.

29. Jamroziak K, Ewa B, Smolewski P, Robey RW, Cebula B, Panczyk M, Jamroziak K, Ewa B, Smolewski P, Robey RW, Cebula B, Panczyk M, Jamroziak K, Ewa B, Smolewski P, Robey RW, Cebula B, Panczyk M: Influence of polymorphisms of ABCB1 gene on the risk of acute adult myeloid leukemia and P-glycoprotein expression in blast cells. Ther Drug Monit 2006, 28(7):707–711.

30. Miller KL, Kelsey KT, Wienneke JK, Moghadasi M, Rei M, Mei L, Wrensch M: No influence of 3435C > T ABCB1 (MDR1) gene polymorphism on risk of adult acute myeloid leukemia and P-glycoprotein expression in blast cells. Ther Drug Monit 2006, 28(7):707–711.

31. Jamroziak K, Ewa B, Cebula B, Janus A, Mirowski M, Tadeusz R: The influence of 3435C > T ABCB1 (MDR1) gene polymorphism on the risk of adult acute myeloid leukemia and P-glycoprotein expression in healthy individuals. Int J Cancer 2007, 120(5):1293–1299.

32. Husein A, Northrup RM, Dvorak M, Schmaler A, Crowell D, Husein A: The influence of polymorphisms of ABCB1 gene on colorectal cancer in the Iranian population. J Gastrointest Hepatol 2007, 22:1678–1682.

33. Mroziewicz PM, Seremak-Mroziewicz A, Semczuk A, Landt O, Bierekowicz G, Drewo K: The significance of C3435T point mutation of the MDR1 gene in endometrial cancer. Int J Gynecol Cancer 2007, 17:705–734.

34. Germignani F, Landi S, Neonilida S-D, Ziaride D, Jolanta L, Rudnal P, Eleonora F, Dana M, Lena K, Vladimir J, Vladimir B, Valeria G, Gioia-Patricola L, Ilaria B, Barale R, Canzian F, Hall J, Boffetta P, Hung RJ, Brennan P: Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis 2007, 28(8):1297–1303.

35. Haenss S, Zimmermann U, Dazert E, Wuck CJ, Dazert P, Siegmund S, Kroemer HK, Warzok RW, Cascorbi I: Influence of polymorphisms of ABCB1 and ABCCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics 2007, 8:301–304.

36. Jaramillo K, Ewa B, Cebula B, Janus A, Mirowski M, Tadeusz R: No influence of 3435C > T ABCB1 (MDR1) gene polymorphism on risk of adult acute myeloid leukemia and P-glycoprotein expression in blast cells. Ther Drug Monit 2006, 28(7):707–711.
55. Sam SS, Vinod T, Kumaran S: Kanipakapatanam Sathyanarayana Reddy, Gopalakrishnan Surianarayanac and Adithan Chandrasekaran. ABCB1 genetic polymorphism and risk of upper aerodigestive tract cancers among smokers, tobacco chewers and alcoholics in an Indian population. Pharmacogenetics Genomics 2007, 17: 861–866.

56. Jarmoziak K, Ewa B, Calka K, Piaskowski S, Urbanska-Rys H, Salagack A, Miovski J, Robak T: Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leukemia Res 2009, 33: 332–335.

57. Rocha V, Porcher R, Fernandes JF, Filon A, Bittencourt H, Silva W Jr, Vilela G, Zanette DL, Ferry C, Larghero J, Devergie A, Ribaud P, Skvortsova Y, Tarnouza R, Gluckman E, Socie G, Zago MA: Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 2009, 23: 545–556.

58. Drain S, Mark A, Catherwood NO, Galligan LI, Maeve R, Hodkinson C, Drake MB, Kettle PJ, Curly Morris TCM, Alexander DH: ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma. Leukemia Lymphoma 2009, 50(4): 566–570.

59. Penna G, Allegra A, Alonci A, Agnennouz M, Garufi A, Cannavo A, Gerace D, Alibrandi A, Musolino C: MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis. Med Oncol 2011, 28: 1549–1554.

60. The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk: Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Treat 2010, 120: 272–275.

61. Chang H, Sun Young R, Hei-Cheul J, Chong Kun I, Sung Hoon N, Jin Ju K, Hyun Cheol C: Association of the ABCB1 3435C > T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol Reports 2010, 23: 271–278.

62. Rao DN, Anuradha C, Vishnupriya S, Sailaja K, Surekha D, Raghunadhara O, Senthil R: Association of an MDR1 gene (C3435T) polymorphism with acute leukemia in India. Asian Pacific J Cancer Prev 2010, 11: 1063–1066.

doi:10.1186/1475-2867-13-46

Cite this article as: Wang et al.: The association between polymorphisms in the MDR1 gene and risk of cancer: a systematic review and pooled analysis of 52 case–control studies. Cancer Cell International 2013 13:46.